Tsirigotis Panagiotis, Bitan Reuven OrMenachem, Resnick Igor B, Samuel Simcha, Ackerstein Aliza, Eladì Sharon, Gesundheit Benjamin, Zilberman Irina, Miron Svetlana, Leubovic Alexander, Slavin Shimon, Shapira Michael Y
Department of Bone Marrow Transplantation & Cancer Immunotherapy, Hadassah, Hebrew University Medical Center, Jerusalem, Israel.
Haematologica. 2006 Jun;91(6):852-5.
We describe our experience with the use of a single non-myeloablative preparative regimen in stem-cell transplantation (NST) in 37 heavily pretreated patients > or =55 years. The conditioning regimen consisted of fludarabine, low-dose busulfan, and antithymocyte globulin. Acute graft-versus-host disease (GVHD) grade III-IV and chronic GVHD developed in 15.6% and 44.4% of cases, respectively. With a median follow-up period of 22 (range 3-113) months, the 1-year overall survival and disease-free-survival were 55% and 53%, respectively, while the overall non-relapse mortality was 35%. In conclusion, reduced intensity stem cell transplantation is feasible and effective in patients > or =55 years. Age per se, should no longer be considered as a contra-indication to stem cell transplantation.
我们描述了在37例年龄≥55岁且经过多次预处理的患者中使用单一非清髓性预处理方案进行干细胞移植（NST）的经验。预处理方案包括氟达拉滨、低剂量白消安和抗胸腺细胞球蛋白。急性移植物抗宿主病（GVHD）III-IV级和慢性GVHD的发生率分别为15.6%和44.4%。中位随访期为22个月（范围3-113个月），1年总生存率和无病生存率分别为55%和53%，而总非复发死亡率为35%。总之，降低强度的干细胞移植在年龄≥55岁的患者中是可行且有效的。年龄本身不应再被视为干细胞移植的禁忌症。
